Traders Purchase High Volume of Call Options on CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC - Get Free Report) saw unusually large options trading on Thursday. Traders bought 1,936 call options on the company. This is an increase of approximately 849% compared to the typical daily volume of 204 call options.

Wall Street Analysts Forecast Growth

CVAC has been the topic of a number of research reports. UBS Group dropped their price objective on CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. JMP Securities reissued a "market outperform" rating and issued a $10.00 price objective on shares of CureVac in a research note on Wednesday, May 28th.

CureVac Price Performance

Shares of NASDAQ CVAC traded up $1.53 during mid-day trading on Thursday, reaching $5.60. The company had a trading volume of 22,916,470 shares, compared to its average volume of 785,499. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.26 billion, a PE ratio of 10.18 and a beta of 2.49. The company has a 50-day moving average price of $3.70 and a two-hundred day moving average price of $3.46. CureVac has a 1-year low of $2.37 and a 1-year high of $5.71.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. On average, equities analysts anticipate that CureVac will post 0.72 earnings per share for the current year.

Hedge Funds Weigh In On CureVac

A number of hedge funds have recently modified their holdings of CVAC. Greenleaf Trust purchased a new position in shares of CureVac during the first quarter valued at $31,000. Integrated Wealth Concepts LLC grew its holdings in shares of CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares in the last quarter. Two Sigma Advisers LP purchased a new position in shares of CureVac during the fourth quarter valued at $48,000. Jump Financial LLC purchased a new position in shares of CureVac during the fourth quarter valued at $55,000. Finally, D. E. Shaw & Co. Inc. purchased a new position in shares of CureVac during the fourth quarter valued at $66,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.